Suppr超能文献

缺乏α-半乳糖苷酶 A 的小鼠肠系膜内皮型一氧化氮合酶解偶联和微血管功能障碍。

Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.

机构信息

Nephrology Division, Dept. of Internal Medicine, Univ. of Michigan, Box 5676, Rm. 1560 MSRB II, 1150 West Medical Center Dr., Ann Arbor, MI 48109-5676.

出版信息

Am J Physiol Gastrointest Liver Physiol. 2014 Jan;306(2):G140-6. doi: 10.1152/ajpgi.00185.2013. Epub 2013 Nov 14.

Abstract

A defect in the gene for the lysosomal enzyme α-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular events. However, gastrointestinal symptoms are often first observed during childhood in these patients and are not well understood. In this study, we demonstrate an age-dependent microvasculopathy of the mesenteric artery (MA) in a murine model of Fabry disease (Gla-knockout mice) resulting from dysregulation of the vascular homeostatic enzyme endothelial nitric oxide synthase (eNOS). The progressive accumulation of Gb3 in the MA was confirmed by thin-layer chromatographic analysis. A total absence of endothelium-dependent dilation was observed in MAs from mice at 8 mo of age, while suppression of ACh-mediated vasodilation was evident from 2 mo of age. Endothelium-independent dilation with sodium nitroprusside was normal compared with age-matched wild-type mice. The microvascular defect in MAs from Fabry mice was endothelium-dependent and associated with suppression of the active homodimer of eNOS. Phosphorylation of eNOS at the major activation site (Ser(1179)) was significantly downregulated, while phosphorylation at the major inhibitory site (Thr(495)) was remarkably enhanced in MAs from aged Fabry mice. These profound alterations in eNOS bioavailability at 8 mo of age were observed in parallel with high levels of 3-nitrotyrosine, suggesting increased reactive oxygen species along with eNOS uncoupling in this vascular bed. Overall, the mesenteric microvessels in the setting of Fabry disease were observed to have an early and profound endothelial dysfunction associated with elevated reactive nitrogen species and decreased nitric oxide bioavailability.

摘要

由于溶酶体酶α-半乳糖苷酶 A(Gla)的基因缺陷,导致法布雷病中糖鞘脂酰基-半乳糖苷三己糖(Gb3)积累,从而导致心脏和脑血管事件导致过早死亡。然而,这些患者的胃肠道症状通常在儿童时期首先观察到,并且尚未得到很好的理解。在这项研究中,我们在法布雷病(Gla-敲除小鼠)的小鼠模型中证明了肠系膜动脉(MA)的年龄依赖性微血管病,这是由于血管稳态酶内皮型一氧化氮合酶(eNOS)的失调所致。通过薄层色谱分析证实了 MA 中 Gb3 的进行性积累。从 8 月龄的小鼠的 MA 中观察到完全缺乏内皮依赖性扩张,而从 2 月龄的小鼠中就已经明显抑制了 ACh 介导的血管舒张。与同龄野生型小鼠相比,用硝普钠诱导的非内皮依赖性扩张是正常的。Fabry 小鼠 MA 中的微血管缺陷是内皮依赖性的,与 eNOS 的活性同源二聚体抑制有关。eNOS 在主要激活位点(Ser(1179))的磷酸化显着下调,而在 MA 中主要抑制位点(Thr(495))的磷酸化显着增强年龄较大的 Fabry 小鼠。在 8 月龄时观察到 eNOS 生物利用度的这些深刻变化与 3-硝基酪氨酸的高水平平行,这表明在该血管床中存在增加的活性氧物质和 eNOS 解偶联。总体而言,法布雷病患者的肠系膜微血管存在与升高的活性氮物种和降低的一氧化氮生物利用度相关的早期和严重的内皮功能障碍。

相似文献

1
Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.
Am J Physiol Gastrointest Liver Physiol. 2014 Jan;306(2):G140-6. doi: 10.1152/ajpgi.00185.2013. Epub 2013 Nov 14.
2
Decreased nitric oxide bioavailability in a mouse model of Fabry disease.
J Am Soc Nephrol. 2009 Sep;20(9):1975-85. doi: 10.1681/ASN.2008111190. Epub 2009 Jul 23.
3
α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
Kidney Int. 2019 Jan;95(1):149-159. doi: 10.1016/j.kint.2018.08.033. Epub 2018 Nov 22.
4
Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.
Mol Genet Metab. 2018 Dec;125(4):338-344. doi: 10.1016/j.ymgme.2018.10.007. Epub 2018 Nov 2.
5
Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.
Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1156-63. doi: 10.1111/j.1440-1681.2008.04984.x. Epub 2008 Jun 18.
6
Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.
Kidney Int. 2014 Jul;86(1):58-66. doi: 10.1038/ki.2013.520. Epub 2014 Jan 8.
7
Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):81-9. doi: 10.1161/ATVBAHA.113.302200. Epub 2013 Oct 24.
8
Role of nitric oxide synthase isoforms for ophthalmic artery reactivity in mice.
Exp Eye Res. 2014 Oct;127:1-8. doi: 10.1016/j.exer.2014.06.018. Epub 2014 Jul 10.
9
Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries.
Am J Physiol Regul Integr Comp Physiol. 2008 Jul;295(1):R59-66. doi: 10.1152/ajpregu.00833.2007. Epub 2008 Apr 30.

引用本文的文献

2
Inflammation and Exosomes in Fabry Disease Pathogenesis.
Cells. 2024 Apr 9;13(8):654. doi: 10.3390/cells13080654.
3
Evaluating the Metabolic Basis of α-Gal A mRNA Therapy for Fabry Disease.
Biology (Basel). 2024 Feb 8;13(2):106. doi: 10.3390/biology13020106.
4
Dysregulated DNA methylation in the pathogenesis of Fabry disease.
Mol Genet Metab Rep. 2022 Sep 26;33:100919. doi: 10.1016/j.ymgmr.2022.100919. eCollection 2022 Dec.
5
Biomarkers in Anderson-Fabry Disease.
Int J Mol Sci. 2020 Oct 29;21(21):8080. doi: 10.3390/ijms21218080.
6
Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.
J Lipid Res. 2020 Nov;61(11):1410-1423. doi: 10.1194/jlr.RA120000909. Epub 2020 Aug 31.
8
α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
Kidney Int. 2019 Jan;95(1):149-159. doi: 10.1016/j.kint.2018.08.033. Epub 2018 Nov 22.
9
Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.
Mol Genet Metab. 2018 Dec;125(4):338-344. doi: 10.1016/j.ymgme.2018.10.007. Epub 2018 Nov 2.
10
Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy.
Front Cardiovasc Med. 2018 Aug 15;5:108. doi: 10.3389/fcvm.2018.00108. eCollection 2018.

本文引用的文献

1
Ca2+-activated K+ channels of small and intermediate conductance control eNOS activation through NAD(P)H oxidase.
Free Radic Biol Med. 2012 Mar 1;52(5):860-70. doi: 10.1016/j.freeradbiomed.2011.11.036. Epub 2011 Dec 23.
3
Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.
Cardiovasc Res. 2011 Feb 1;89(2):290-9. doi: 10.1093/cvr/cvq333. Epub 2010 Oct 21.
4
Endothelial nitric oxide synthase transgenic models of endothelial dysfunction.
Pflugers Arch. 2010 Nov;460(6):965-74. doi: 10.1007/s00424-010-0867-4. Epub 2010 Aug 10.
5
eNOS uncoupling and endothelial dysfunction in aged vessels.
Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1829-36. doi: 10.1152/ajpheart.00230.2009. Epub 2009 Sep 18.
6
Decreased nitric oxide bioavailability in a mouse model of Fabry disease.
J Am Soc Nephrol. 2009 Sep;20(9):1975-85. doi: 10.1681/ASN.2008111190. Epub 2009 Jul 23.
7
Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.
Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1156-63. doi: 10.1111/j.1440-1681.2008.04984.x. Epub 2008 Jun 18.
8
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
J Mol Cell Cardiol. 2007 Dec;43(6):780-91. doi: 10.1016/j.yjmcc.2007.08.015. Epub 2007 Aug 31.
9
Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
J Biol Chem. 2007 Jul 20;282(29):20960-7. doi: 10.1074/jbc.M702436200. Epub 2007 May 29.
10
Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.
J Inherit Metab Dis. 2007 Apr;30(2):184-92. doi: 10.1007/s10545-007-0521-2. Epub 2007 Mar 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验